Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

NCT00517361 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped This study has been terminated due to poor accrual

Conditions

Metastatic Breast Cancer

Interventions

DRUG: carboplatin
DRUG: bevacizumab

Sponsor

University of Chicago

Collaborators

[object Object]